| Trial, NCT* . | Catheter system . | Design, (randomisation ratio) . | Sample size . | Inclusion criteria . | Primary efficacy outcome . | Estimated trial completion . |
|---|---|---|---|---|---|---|
| SPYRAL HTN-ON MED Expansion, NCT02439775 | Symplicity Spyral (multi-electrode RF) | Bayesian adaptive design, RDN vs sham (1:1) | 340 | Uncontrolled office and 24-hour BP on 1-3 antihypertensive drugs | Change in 24-hour SBP at 6 months | 2026 |
| RADIANCE II, NCT03614260 | Paradise (US) | RDN vs sham (1:1) | 225 | Uncontrolled stage II hypertension (office and daytime ambulatory BP) in absence of antihypertensive drugs | Change in daytime ambulatory SBP at 2 months | 2022 |
| TARGET BP OFF-MED, NCT03503773 | Peregrine (ethanol injection via microneedles) | RDN vs sham (1:1) | 90 | Uncontrolled office and 24-hour BP in absence of antihypertensive drugs | Change in 24-hour ambulatory SBP at 2 months | 2023 |
| TARGET BP I, NCT02910414 | Peregrine (ethanol injection via microneedles) | RDN vs sham (1:1) | 300 | Uncontrolled office and 24-hour BP on 2-5 antihypertensive drugs | Change in ambulatory 24-hour SBP at 3 months | 2025 |
| Trial, NCT* . | Catheter system . | Design, (randomisation ratio) . | Sample size . | Inclusion criteria . | Primary efficacy outcome . | Estimated trial completion . |
|---|---|---|---|---|---|---|
| SPYRAL HTN-ON MED Expansion, NCT02439775 | Symplicity Spyral (multi-electrode RF) | Bayesian adaptive design, RDN vs sham (1:1) | 340 | Uncontrolled office and 24-hour BP on 1-3 antihypertensive drugs | Change in 24-hour SBP at 6 months | 2026 |
| RADIANCE II, NCT03614260 | Paradise (US) | RDN vs sham (1:1) | 225 | Uncontrolled stage II hypertension (office and daytime ambulatory BP) in absence of antihypertensive drugs | Change in daytime ambulatory SBP at 2 months | 2022 |
| TARGET BP OFF-MED, NCT03503773 | Peregrine (ethanol injection via microneedles) | RDN vs sham (1:1) | 90 | Uncontrolled office and 24-hour BP in absence of antihypertensive drugs | Change in 24-hour ambulatory SBP at 2 months | 2023 |
| TARGET BP I, NCT02910414 | Peregrine (ethanol injection via microneedles) | RDN vs sham (1:1) | 300 | Uncontrolled office and 24-hour BP on 2-5 antihypertensive drugs | Change in ambulatory 24-hour SBP at 3 months | 2025 |
*NCTs found at ClinicalTrials.gov. BP: blood pressure; RDN: renal denervation; RF: radiofrequency; SBP: systolic blood pressure; US: ultrasound
| Trial, NCT* . | Catheter system . | Design, (randomisation ratio) . | Sample size . | Inclusion criteria . | Primary efficacy outcome . | Estimated trial completion . |
|---|---|---|---|---|---|---|
| SPYRAL HTN-ON MED Expansion, NCT02439775 | Symplicity Spyral (multi-electrode RF) | Bayesian adaptive design, RDN vs sham (1:1) | 340 | Uncontrolled office and 24-hour BP on 1-3 antihypertensive drugs | Change in 24-hour SBP at 6 months | 2026 |
| RADIANCE II, NCT03614260 | Paradise (US) | RDN vs sham (1:1) | 225 | Uncontrolled stage II hypertension (office and daytime ambulatory BP) in absence of antihypertensive drugs | Change in daytime ambulatory SBP at 2 months | 2022 |
| TARGET BP OFF-MED, NCT03503773 | Peregrine (ethanol injection via microneedles) | RDN vs sham (1:1) | 90 | Uncontrolled office and 24-hour BP in absence of antihypertensive drugs | Change in 24-hour ambulatory SBP at 2 months | 2023 |
| TARGET BP I, NCT02910414 | Peregrine (ethanol injection via microneedles) | RDN vs sham (1:1) | 300 | Uncontrolled office and 24-hour BP on 2-5 antihypertensive drugs | Change in ambulatory 24-hour SBP at 3 months | 2025 |
| Trial, NCT* . | Catheter system . | Design, (randomisation ratio) . | Sample size . | Inclusion criteria . | Primary efficacy outcome . | Estimated trial completion . |
|---|---|---|---|---|---|---|
| SPYRAL HTN-ON MED Expansion, NCT02439775 | Symplicity Spyral (multi-electrode RF) | Bayesian adaptive design, RDN vs sham (1:1) | 340 | Uncontrolled office and 24-hour BP on 1-3 antihypertensive drugs | Change in 24-hour SBP at 6 months | 2026 |
| RADIANCE II, NCT03614260 | Paradise (US) | RDN vs sham (1:1) | 225 | Uncontrolled stage II hypertension (office and daytime ambulatory BP) in absence of antihypertensive drugs | Change in daytime ambulatory SBP at 2 months | 2022 |
| TARGET BP OFF-MED, NCT03503773 | Peregrine (ethanol injection via microneedles) | RDN vs sham (1:1) | 90 | Uncontrolled office and 24-hour BP in absence of antihypertensive drugs | Change in 24-hour ambulatory SBP at 2 months | 2023 |
| TARGET BP I, NCT02910414 | Peregrine (ethanol injection via microneedles) | RDN vs sham (1:1) | 300 | Uncontrolled office and 24-hour BP on 2-5 antihypertensive drugs | Change in ambulatory 24-hour SBP at 3 months | 2025 |
*NCTs found at ClinicalTrials.gov. BP: blood pressure; RDN: renal denervation; RF: radiofrequency; SBP: systolic blood pressure; US: ultrasound
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
